Trastuzumab all are true EXCEPT:
Causes upregulation of HER2/neu REF: Lippincott's pharmacology 6th edition 653, Goodman & Gillman's 11'1' edition page 901, http://en.wikipedia.org/wiki/Trastuzumab "It has been suggested that trastuzumab induces some of its effect by downregulation of HER2/neu not upregulation" Trastuzumab: Herceptin (Trastuzumab) is a humanized antibody directed against the HER-2 antigen that is overexpressed on the tumor cell surface in approximately 25% of breast cancer patients. Trastuzumab is approved as intravenous infusion in HER2/neu overexpressing metastatic breast cancer in combination with paclitaxel as initial treatment or as monotherapy following chemotherapy relapse. Trastuzumab also is synergistic with other cytotoxic agents, but only in HER2/neuoverexpressing cancers. Trastuzumab is a humanized monoclonal antibody that binds to the domain IV of the extracellular segment of the HER2/neu receptor It has been suggested that trastuzumab induces some of its effect by downregulation of HER2/ neu Herceptinus e is associated withinfusion-relatedhypotension , flushing andbronchoconstriction, and skin rash but no bone marrow toxicity Herceptin appears to sensitize patients to cardiotoxicity, an impoant concern in patients also receiving doxorubicin.
Shows better response in combination with paclitaxel
Used in metastatic breast cancer
Causes upregulation of HER2/neu
Do not causes bone marrow toxicity